8 Amendments of Linda McAVAN related to 2016/2057(INI)
Amendment 3 #
Draft opinion
Paragraph 1
Paragraph 1
1. Recalls that Sustainable Development Goal 3, with nine quantitative and four qualitative targets, clearly states that by 2030 everyone should have access to good mental and physical health throughout their lives, which cannot be achieved without efficient and effective investment in new improved prevention, treatment and diagnostic tools; underlines that, each year, 100 million people fall into poverty because of health costs which are disproportionate to their incomes, and that, according to the WHO, over one third of the world’s population, with over 50 % in Africa, does not have access to medicines;
Amendment 17 #
Draft opinion
Paragraph 1 a (new)
Paragraph 1 a (new)
1a. Stresses the importance of developing a comprehensive access to medicines policy that ensures that all EU policies (global public health, development, research and trade) are consistent with, and beneficial for, access to affordable medicines for citizens in the EU and low-and middle-income countries alike;
Amendment 28 #
Draft opinion
Paragraph 2
Paragraph 2
Amendment 36 #
Draft opinion
Paragraph 2 a (new)
Paragraph 2 a (new)
2a. Welcomes the option for voluntary licensing that allows to produce generic drugs with allowance and adapted remuneration of the originator at reduced prices; reminds that in case of national emergency or other circumstances of extreme urgency TRIPS allows compulsory licensing as enables developing countries to produce generics without consent of the originator; stresses that originators usually grant waivers to LDCs and low income countries that exempts them from TRIPS provisions;
Amendment 42 #
Draft opinion
Paragraph 3
Paragraph 3
3. Supports competition in generic medicines within the negotiated rules, which allows broad access to medicines in LMICs; calls, in particular, for the EU to support actively governments that use the available legal measures, including TRIPS safeguards and flexibilities, to protect and promote public health; calls also for the EU to immediately stop targeting countries such as India that have implemented progressive TRIPS-compliant IP policies which promote access to medicines, through its watch-list of ‘priority countries’ in case of emergency;
Amendment 50 #
Draft opinion
Paragraph 3 a (new)
Paragraph 3 a (new)
3a. Stresses that in LMICs limited accessibility of health medical tools is - next to affordability - also linked to issues such as weak distribution systems and insufficient regulatory capacities, and that for most poverty-related and neglected tropical diseases, acceptable, safe and effective vaccines, drugs and diagnostics are still lacking; calls on the Commission and Member States to step up efforts to address this persisting research gap, and to support LMICs in building respective capacities;
Amendment 55 #
Draft opinion
Paragraph 4
Paragraph 4
4. Stresses that, without basic transparency of research and development costs to originator companies and information on the actual prices paid for medicines across the EU, any discussion on fair medicine prices remains impossiblfair pricing is difficult to determine; recalls the Commission’s commitment to greater transparency of EU positions, specific legal proposals, and negotiating texts in the TTIP negotiations;
Amendment 66 #
Draft opinion
Paragraph 5
Paragraph 5
5. Urges to take advantage of the ongoing review process of the EU Tiered Pricing Regulation to repeal it unless it can be amended, in close collaboration with the Commission’s Directorates- General for International Cooperation and Development (DG DEVCO) and for Health and Food Safety (DG SANTÉ), in order to support all measures that countries have at their disposal to ensureopen a broader and transparent discussion on pricing regulation and strategies that improve access to affordable access to medicines.;